99% Savings - Buy Just @1 Rs X
Ibires L Nexpules is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Adult |
|
Geriatric |
|
Is the use of Ibires L Nexpules safe for pregnant women?
Ibires Nexhaler may cause moderate side effects during pregnancy. If you feel its harmful effects, then stop taking this drug immediately, and do not take Ibires Nexhaler again without your doctor's advice.
Is the use of Ibires L Nexpules safe during breastfeeding?
Ibires Nexhaler can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Ibires L Nexpules on the Kidneys?
Ibires Nexhaler has very mild side effects on the kidneys.
What is the effect of Ibires L Nexpules on the Liver?
Using Ibires Nexhaler does not have any harmful effects on the liver.
What is the effect of Ibires L Nexpules on the Heart?
Side effects of Ibires Nexhaler rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Ibires L Nexpules unless your doctor advises you to do so -
Is this Ibires L Nexpules habit forming or addictive?
Ibires L Nexpules is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Ibires L Nexpules as you may feel sleepy.
Is it safe?
Ibires L Nexpules is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Ibires L Nexpules is not used to treat mental disorders.
Interaction between Food and Ibires L Nexpules
It is safe to take Ibires L Nexpules with food.
Interaction between Alcohol and Ibires L Nexpules
Consult your doctor before consuming alcohol while taking Ibires L Nexpules as it can have severe side effects.
Ibires Nexhaler is a brand name of levosalbutamol (also known as levalbuterol) it is available in the form of tablet, syrup, respules, transpules, and inhaler. It belongs to the class of drugs known as beta-2-adrenergic agonists (bronchodilators). It is a prescription drug which is used to provide relief from bronchospasm in asthma and COPD (chronic obstructive pulmonary disease). Patients with long-term respiratory infections are also prescribed Ibires Nexhaler to get instant relief from breathing difficulties.
Yes, Ibires Nexhaler might cause anxiety. It is a rare side effect of this drug and the exact cause behind anxiety is not known. If you are experiencing anxiety or restlessness after taking this drug, then you are advised to discuss it with your doctor immediately.
The dosage and duration of Ibires Nexhaler may vary depending upon the age and medical condition of the patient. Hence you are advised to take Ibires Nexhaler as advised by your doctor.
Yes, Ibires Nexhaler can help with coughing. Excessive mucus on the lining of the airway causes decreased airflow and coughing. Ibires Nexhaler widens the airway through its vasodilation actions which provide relief to the patients from coughing.
No, Ibires Nexhaler does not cause weight gain. It has not been reported by the patients who are taking this drug. If you are experiencing rapid weight gain after taking this drug, then it might be due to some other reason and you are advised to discuss it with your doctor.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xopenex® (levalbuterol hydrochloride)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 763-765